Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying anti-rheumatic drugs or biological agents are not always effective, hence driving the demand for new experimental therapeutics. The antiproliferative capacity of proteasome inhibitors (PIs) has received consid...

Descripción completa

Detalles Bibliográficos
Autores principales: Verbrugge, Sue Ellen, Scheper, Rik J, Lems, Willem F, de Gruijl, Tanja D, Jansen, Gerrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308859/
https://www.ncbi.nlm.nih.gov/pubmed/25889583
http://dx.doi.org/10.1186/s13075-015-0529-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308859/
https://www.ncbi.nlm.nih.gov/pubmed/25889583
http://dx.doi.org/10.1186/s13075-015-0529-1

Ejemplares similares